Helmut Friess, Jan M. Langrehr, Helmut Oettle, Jochen Raedle, Marco Niedergethmann, Christian Dittrich, Dieter K. Hossfeld, Herbert Stöger, Bart Neyns, Peter Herzog, Pascal Piedbois, Frank Dobrowolski, Werner Scheithauer, Robert Hawkins, Frieder Katz, Peter Balcke, Jan Vermorken, Simon Van Belle, Neville Davidson, Albert Abad Esteve, Daniel Castellano, Jörg Kleeff, Adrien A. Tempia-Caliera, Andreas Kovar, Johannes Nippgen
- Background Anti-angiogenic treatment is believed to have at least cystostatic effects in highly vascularized tumours like pancreatic cancer. In this study, the treatment effects of the angiogenesis inhibitor Cilengitide and gemcitabine were compared with gemcitabine alone in patients with advanced unresectable pancreatic cancer. Methods A multi-national, open-label, controlled, randomized, parallel-group, phase II pilot study was conducted in 20 centers in 7 countries. Cilengitide was administered at 600 mg/m2 twice weekly for 4 weeks per cycle and gemcitabine at 1000 mg/m2 for 3 weeks followed by a week of rest per cycle. The planned treatment period was 6 four-week cycles. The primary endpoint of the study was overall survival and the secondary endpoints were progression-free survival (PFS), response rate, quality of life (QoL), effects on biological markers of disease (CA 19.9) and angiogenesis (vascular endothelial growth factor and basic fibroblast growth factor), and safety. An ancillary study investigated the pharmacokinetics of both drugs in a subset of patients. Results Eighty-nine patients were randomized. The median overall survival was 6.7 months for Cilengitide and gemcitabine and 7.7 months for gemcitabine alone. The median PFS times were 3.6 months and 3.8 months, respectively. The overall response rates were 17% and 14%, and the tumor growth control rates were 54% and 56%, respectively. Changes in the levels of CA 19.9 went in line with the clinical course of the disease, but no apparent relationships were seen with the biological markers of angiogenesis. QoL and safety evaluations were comparable between treatment groups. Pharmacokinetic studies showed no influence of gemcitabine on the pharmacokinetic parameters of Cilengitide and vice versa. Conclusion There were no clinically important differences observed regarding efficacy, safety and QoL between the groups. The observations lay in the range of other clinical studies in this setting. The combination regimen was well tolerated with no adverse effects on the safety, tolerability and pharmacokinetics of either agent.
MetadatenAuthor: | Helmut Friess, Jan M. Langrehr, Helmut Oettle, Jochen Raedle, Marco Niedergethmann, Christian Dittrich, Dieter K. Hossfeld, Herbert Stöger, Bart Neyns, Peter Herzog, Pascal Piedbois, Frank Dobrowolski, Werner Scheithauer, Robert Hawkins, Frieder Katz, Peter Balcke, Jan Vermorken, Simon Van Belle, Neville Davidson, Albert Abad Esteve, Daniel Castellano, Jörg Kleeff, Adrien A. Tempia-Caliera, Andreas Kovar, Johannes Nippgen |
---|
URN: | urn:nbn:de:hebis:30-36576 |
---|
DOI: | https://doi.org/10.1186/1471-2407-6-285 |
---|
Parent Title (English): | BMC Cancer 2006, 6:285 |
---|
Document Type: | Article |
---|
Language: | English |
---|
Year of Completion: | 2006 |
---|
Year of first Publication: | 2006 |
---|
Publishing Institution: | Universitätsbibliothek Johann Christian Senckenberg |
---|
Release Date: | 2007/01/16 |
---|
Volume: | 6 |
---|
Issue: | 285 |
---|
Note: | This article is available from: http://www.biomedcentral.com/1471-2407/6/285 © 2006 Friess et al; licensee BioMed Central Ltd.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
---|
HeBIS-PPN: | 191400726 |
---|
Institutes: | Medizin / Medizin |
---|
Dewey Decimal Classification: | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
---|
Licence (German): | Creative Commons - Namensnennung 2.0 |
---|